Purple Biotech Reports Positive NT219 Data
Ticker: PPBT · Form: 6-K · Filed: Apr 28, 2025 · CIK: 1614744
Sentiment: bullish
Topics: clinical-trial-data, oncology, press-release
TL;DR
Purple Biotech's NT219 shows promise in colorectal and head/neck cancer trials.
AI Summary
On April 28, 2025, Purple Biotech Ltd. announced positive data from its Phase 1b study of NT219 in combination with nivolumab for patients with metastatic colorectal cancer and head and neck squamous cell carcinoma. The study, presented at the AACR Annual Meeting, showed encouraging objective response rates and safety profiles for both indications.
Why It Matters
Positive clinical trial data for NT219 could advance its development for difficult-to-treat cancers, potentially offering new treatment options for patients.
Risk Assessment
Risk Level: medium — Clinical trial results are inherently uncertain, and further development and regulatory approval are required.
Key Numbers
- Phase 1b — Study Phase (Indicates early-stage clinical trial)
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer of the report
- NT219 (drug) — Investigational drug
- nivolumab (drug) — Drug used in combination therapy
- AACR Annual Meeting (event) — Where data was presented
- April 28, 2025 (date) — Date of press release
FAQ
What specific objective response rates were observed for NT219 in colorectal cancer patients?
The filing states encouraging objective response rates were observed, but does not provide specific numerical percentages for colorectal cancer in this summary.
What was the safety profile of NT219 in combination with nivolumab?
The press release attached as Exhibit 99.1 indicates an encouraging safety profile was observed for both indications.
Which specific cancers were studied in the Phase 1b trial of NT219?
The trial studied metastatic colorectal cancer and head and neck squamous cell carcinoma.
When was the press release announcing these results issued?
The press release was issued on April 28, 2025.
What is the primary purpose of this 6-K filing?
This 6-K filing is to report a press release issued by Purple Biotech Ltd. regarding positive clinical data for its drug NT219.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 28, 2025 regarding PURPLE BIOTECH LTD. (PPBT).